false
OasisLMS
Catalog
LUGPA 2025 CME Enduring Program: Operationalizing ...
2025 CME Program Part 9
2025 CME Program Part 9
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Jeffrey Speer discusses operationalizing radioligand therapies in independent urology practices, emphasizing theranostics as both a clinical innovation and strategic business model. He highlights the design and workflow considerations for integrating advanced molecular imaging and targeted therapies sustainably within private practices. Speer underscores the importance of multidisciplinary partnerships, revenue operations, compliance, and quality patient care to successfully implement radioligand therapy. <br /><br />Dr. Oto from the University of Chicago provides an in-depth overview of prostate MRI, focusing on prostate anatomy, the PI-RADS scoring system, and common diagnostic pitfalls. He explains the differences in imaging characteristics across prostate zones and illustrates how to interpret multiparametric MRI features for cancer detection. Oto discusses challenges such as prostatitis, hemorrhage, and focal atrophy that can mimic cancer, stressing the need for high-quality imaging and collaboration between radiologists and urologists. He also points to emerging quantitative MRI techniques and AI tools aimed at improving diagnostic accuracy. Both presentations emphasize integrating advanced imaging and therapies into clinical practice for improved prostate cancer care.
Keywords
radioligand therapy
theranostics
prostate MRI
PI-RADS scoring system
multiparametric MRI
prostate cancer diagnostics
×
Please select your language
1
English